BACE Antibodies

Santa Cruz Biotechnology features a diverse variety of BACE monoclonal antibodies for the detection and analysis of beta-site amyloid precursor protein cleaving enzyme (BACE), a critical enzyme involved in the production of amyloid-beta peptides. BACE monoclonal antibodies support various research applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). BACE plays a significant role in the pathogenesis of Alzheimer's disease by facilitating the cleavage of amyloid precursor protein (APP), leading to the accumulation of amyloid plaques in the brain. Understanding the function and regulation of BACE is essential for developing therapeutic strategies aimed at mitigating the effects of neurodegenerative diseases. The study of BACE and its interactions can provide insights into the molecular mechanisms underlying cognitive decline and neuronal damage. Research focused on BACE has revealed important connections between enzyme activity and the progression of neurodegenerative conditions. Investigating BACE activity patterns helps scientists better understand the development of amyloid plaques and their impact on brain function. Exploring BACE mechanisms continues to yield valuable information about potential therapeutic targets in neurological disorders. Santa Cruz Biotechnology monoclonal antibodies for BACE research support scientists worldwide in their mission to advance our understanding of Alzheimer's disease and develop effective treatments.